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ABSTRACT 
Objective: To determine the seroprevalence of varicella-zoster 
virus antibodies in a wide age range of healthy subjects in 
Thailand. 
Design and Methods: In 1994, blood samples were collected 
from 559 volunteers aged 4 months to 77 years from the 
Bangkok area; questionnaires about socioeconomic back- 
ground and history of chickenpox or herpes zoster were also 
completed. Serum samples were assayed for specific varicella- 
zoster virus (VZV) IgG antibodies using a commercial enzyme- 
linked immunosorbent assay kit. 
Results: The seroprevalence rate (61.4% overall) increased with 
age: less than 1 year, 10.2%; 1 to 4 years, 24.1%; 5 to 9 years, 
62.5%; IO to 14 years, 70.4%; 15 to 19 years, 78.9%; 20 to 
29 years, 69.2%; 30 to 39 years, 96.1%; 40 to 49 years, 100%; 
and 50 years and older, 98.0%. No significant differences in the 
VZV antibody prevalence with respect to gender, family size, or 
family income were seen. There was good correlation between 
varicella history and seropositivity: 92.9% of subjects with a 
varicella history were seropositive. 
Conclusions: In this urban population, approximately one in 
three adolescents and young adults lacked natural immunity 
against varicella. The results suggest that vaccination programs 
in Thailand and probably other tropical countries should include 
susceptible adolescents and adults who are at high risk of 
developing severe varicella and resultant complications. 
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Varicella-zoster virus (VZV), the etiologic agent for both 
varicella (chickenpox) and herpes zoster is distributed 
wor1dwide.l In temperate countries, primary varicella- 
zoster virus infection, varicella, is a highly communicable 
disease that occurs mainly in childhood.2 In tropical and 
subtropical countries, where varicella immunity is not 
universal until a later age, more cases are seen in ado- 
lescents and young adults. 3,4 In childhood, varicella is gen- 
erally a benign exanthematous disease, but when it occurs 
in older age groups, the disease tends to be more severe 
and the risk of complications is greateris 
A good understanding of the epidemiology of dis- 
ease, with detailed information about the immunity and 
susceptibility of the population, is required to provide 
appropriate and cost-effective health control planning, 
including vaccination programsAlthough varicella is noti- 
fiable in many countries, the disease, probably because of 
its benign nature, is generally under-reported.‘Therefore, 
the monitoring of reported clinical cases is considered to 
be an unreliable method of acquiring details of the inci- 
dence and prevalence of varicella. Serologic surveys have 
been used to provide information about varicella immu- 
nity,$-13 and this information, with details about previous 
varicella history, demographics, and socioeconomic status 
can be used to build an accurate epidemiologic picture. 
In Thailand, there have been no studies of the seroepi- 
demiology of varicella, except for a limited survey carried 
out in the early 1980s in immunocompromised children, 
healthy young adults, and a few healthy children.” 
A seroepidemiologic survey of a healthy Thai popu- 
lation was carried out in 1994 to determine the sero- 
prevalence of VZV antibodies in a wide age range of 
subjects.The relation between serologic findings and var- 
ious epidemiologic and demographic factors and clinical 
history of the disease was also assessed. The results of 
this survey are presented here. 
MATERIAL AND METHODS 
From April 1994 to July 1994, healthy subjects from 4 
months to 77 years of age were recruited, on a voluntary 
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basis without any randomization, to take part in the sur- 
vey after they or, in the case of the children, their parents 
had provided written informed consent. A total of 559 
subjects who were living either in Bangkok or in the 
vicinity (suburbs or a satellite town) at the time of the 
survey were enrolled to ensure that there were at least 
50 subjects in each of the following nine age groups: 
under 1 year (n = 108 subjects), 1 to 4 years (n = 58) 5 
to 9 years (n = 64) 10 to 14 years (n = 71) 15 to 19 years 
(n = 52), 20 to 29 years (n = 52) 30 to 39 years (n = 52) 
40 to 49 years (n = 51) and 50 years and older (n = 51). 
Adults and children were recruited, according to their 
age group, from a variety of locations, including well-baby 
clinics (<l y), daycare centers (l-5 y), schools (5-14 y), 
hospitals (medical and nursing students aged 19-20 y), 
and health clinics (adults in yearly check-up schedules). 
A questionnaire was completed for each subject dur- 
ing an interview with the subject or the parents. Ques- 
tionnaires collected details about socioeconomic 
background (family size and income) as well as any his- 
tory of chickenpox or herpes zoster (the approximate 
date when an incident occurred was included whenever 
it was known). 
Blood samples were taken from each subject and the 
separated serum was stored at -20°C until testing. Spe- 
cific VZV IgG antibodies were determined using a com- 
mercial enzyme-linked immunosorbent assay (ELISA) kit 
(Enaygnost, anti-VZV/IgG, Behringwerke, Germany) 
according to the manufacturer’s instructions. 
Briefly, the serum samples and an anti-VZV reference 
reagent (positive antibody control) were prediluted to 
1:2 1, with the buffer supplied, and dispensed into micro- 
wells containing VZV antigen and control antigen, yield- 
ing a final test dilution of 1:231. The test plate was 
incubated for 1 hour at 37°C. Wells were washed three 
times using an automated plate washer, before anti-human 
IgG/peroxidase conjugate was added.The plate was incu- 
bated again for 1 hour at 37°C and washed three times 
(leaving the plate to stand for l-2 minutes during each 
washing) before the substrate chromogen was added to 
each well.The plate was then incubated, while protected 
from the light, at 18” to 25°C for 30 minutes. Stopping 
solution was then added to each well. 
The final absorbance values of plates were read at 
450 nm in an automated photometer (Titertek Multiscan 
Plus, Flow Laboratories, Irvine, Scotland). For each serum 
sample, the delta absorbance value was calculated as the 
difference between the absorbances of the VZV antigen 
well and the control antigen well. 
For the qualitative evaluation of the test samples, 
delta absorbance values 0.2 or higher were considered to 
be positive and to indicate previous exposure to VZV 
infection, whereas values less than 0.1 were considered 
to be negative and to indicate susceptibility to VZV infec- 
tion. Serum samples that had values between 0.1 and 0.2 
had to be retested; if the new value could still not be 
defined as negative or positive, the result was classed as 
“equivocal.” 
Data were analyzed using multivariate analysis. 
RESULTS 
Specific VZV IgG antibodies were detected in serum sam- 
ples from 343 of the 559 subjects enrolled in the survey, 
an overall seroprevalence rate of 61.4%.There were no 
significant differences in the VZV antibody prevalence 
with regard to gender, family size, or family income (data 
not presented). 
The percentage of seropositive subjects increased 
with age from 24.1% in the 1 to 4 year age group to 100% 
in the 40 to 49 year age group; in the 50 years and older 
age group, all but one subject (a 56year-old male) were 
seropositive (Figure 1). 
However, in the under 1 year age group, which 
included 108 infants aged 4 to 9 months (4-5 mo, n = 19; 
6-7 mo, n = 63; 8-9 mo, n = 26) the seropositivity rate 
decreased with age from 3 1.6% in the 4- to 5-month-old 
infants to 3.8% in the S- to 9-month-old infants (Figure 2). 
No l-year-old children were included in the survey; but 
among the 2- and S-year-old children (2 y, n = 6; 3 y, n = 
36) the seroprevalence was 23.8%. 
A history of clinical varicella was reported in 226 
subjects. More than 60% of these incidents had occurred 
more than 2 years earlier and nearly 40% more than 10 
years before.There was good correlation between a his- 
tory of varicella and seropositivity: 92.9% (210 of 226) of 
subjects with a reported history of varicella were seropos- 
itive. However, for 39.6% (114 of 288) of subjects who 
were seropositive, there was no history of clinical vari- 
cella (Figure 3). 
A subanalysis of the correlation of a history of chick- 
enpox with seropositivity in children under 5 years of age 
was also performed: 14 children had a positive history 
and 138 had no history of the disease. In this age group, 
the correlation between a positive history and seroposi- 
tivity (85.7%; 12 of 14) was similar to that in the whole 
study population, whereas the correlation between a neg- 














Figure 1. Prevalence rates of varicella-zoster virus antibody in all age 
groups. 
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Figure 2. Varicella-zoster virus seroprevalence for infants under 3 
years of age. 
ative history and seronegativity was much better (i.e., 
only 9.4% [13 of 1251 of subjects who had no history of 
clinical chickenpox were seropositive). 
Twenty-three (4.1%) subjects, aged from 11 to 61 
years, reported that they had had herpes zoster in the 
past. In four cases, the time of the incident was not 
reported; in 13 cases, the incident was reported to have 
occurred more than 5 years earlier; in five cases, it had 
occurred within 1 to 5 years, and in one case, within 1 
yearThus, it was not possible to estimate the average age 
at which the incidents occurred.All but one of these 
23 subjects were seropositive for VZV at the time of the 
survey. 
DISCUSSION 
The epidemiology of primary VZV infection is recognized 
as being different in tropical and temperate regi0ns.l In 
the developed, industrialized countries in temperate 
regions of the world, exposure to VZV, as measured by a 
history of the disease or by the presence of anti-VZV anti- 
bodies is almost 100% by late middle age.l* Serologic sur- 
veys have shown that anti-VZV seropositivity rates were 
100% in subjects 15 years of age or older in the United 
States,* almost 80% by 15 years of age in Great Britain,‘* 
Positive 
history 
n = 226 
Figure 3. Clinical varicella history. 
Negative 
history 
n = 288 
93.8% in 15- to 19-year-olds in the Czech Republic,lj and 
100% in subjects aged 25 to 29 years in Japan.’ However, 
recently it has been recognized that the age at which the 
disease occurs has shifted to older groups in the United 
Kingdom and America. 16-18 
In tropical regions, the disease apparently occurs at 
a much later age: 71.5% of cases were in adults aged 20 
years or over in Sri Lanka,3 in Somalia 46% of cases 
occurred in people over 15 years of age,19 and in the 
West Indies less than 10% of the population had experi- 
enced the infection before the age of 15 years.ZoThe pop- 
ulation studied in the seroepidemiologic survey presented 
here was not based on random sampling and may bear 
some selection bias. Nevertheless, the results show that 
26% of 15- to 29-year-old adolescents and young adults 
were seronegative for specific VZV antibodies are in 
agreement with the findings in tropical regions and with 
the results of the earlier serologic study conducted in 
Thailand in 1985 in which almost 30% of young adults 
were found to be susceptible to the infectionlo The 
results are also in line with other serologic surveys car- 
ried out in tropical regions, which have shown similar 
age distributions for varicella seroprevalence in Singa- 
pore and India. *,11 Outbreaks of varicella in immigrants 
from tropical countries to temperate regions also have 
shown the susceptibility of young adults from such coun- 
tries to the disease.21-23 
In developed countries, varicella has been linked to 
social factors.24 However, in the present study, there were 
no significant differences in seroprevalence with regard 
to family size or income (data not presented). 
An earlier investigation in the United States, which 
showed that infants born to mothers with detectable vari- 
cella antibody almost always had detectable antibody at 
birth, also reported that 50% of infants had lost their anti- 
bodies by approximately 6 months of age.25 The findings 
in this study are similar to those in the earlier investiga- 
tion; that is, 3 1.6% of the youngest (4-5 mo) infants com- 
pared to 82.7% of the 20- to 39-year age groups (the age 
group likely to contain the majority of mothers) had anti- 
bodies to varicella. The decline of the levels of the 
acquired maternal antibody with age in the infants in this 
study, which was also seen in the earlier investigation, 
would suggest that by 9 months of age practically all 
infants would no longer be passively protected against the 
disease. Unfortunately this could not be confirmed 
because children between the ages of 9 months and 2 
years were not included in the study. From 2 years of 
age, the seroprevalence increased with age. 
A high correlation between a history of varicella 
and seropositivity was seen in the study. This suggests 
that individuals requiring vaccination may be identified 
without recourse to serologic testing. However, since a 
number of subjects who had no reported history of clm- 
ical varicella were found to be seropositive, it may be 
that the anamnesis of the subjects or their parents about 
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varicella symptoms is not absolute.The important role 
of memory in this regard seems to be confirmed by the 
much better correlation between “no history” and 
seronegativity in the under 5-year-old age group in this 
study. In addition, subclinical varicella-zoster infections, 
which have been estimated to occur in 4% or less of 
individuals following household exposure,26 may con- 
tribute to this finding. 
Although the majority of the people in developing 
countries live in rural areas rather than an urban setting 
similar to the area where this study was conducted, no 
studies appear to have been reported that make direct 
comparisons of the epidemiology of varicella in rural and 
urban areas in the tropics. However, the findings of epi- 
demiologic studies in Somalia and in a densely populated 
village in rural West Bengal, which showed that at least 
46% of the varicella cases occurred in adults over 15 
years of age, are similar to those reported in this study.4a19 
Morever, since the symptoms of chickenpox are well 
known and easily recognized even by the lay public, it 
seems likely that a history of varicella will be as reliable 
in rural areas as it is in the urban setting of this study. 
It has been suggested that there are no apparent dif- 
ferences in the geographic distribution of herpes zoster, 
but there is a paucity of published dataAlthough, in India, 
where the primary infection occurs at a relatively later 
age, the incidence of zoster was decreased compared to 
that in temperate regions. *’ In this study, a positive her- 
pes zoster history was reported in only 4.1% of subjects, 
but the majority of the subjects in the survey were less 
than 15 years of age. Unfortunately, because of the impre- 
cise histories of these incidents and the impossibility of 
calculating the age of the subjects when the incidents 
occurred, it was not possible to make a meaningful esti- 
mate of the “age incidence” of zoster. More precise data 
on the incidence of zoster in tropical countries would be 
of interest. 
The results of this study suggest that vaccination pro- 
grams in Thailand, and probably in other tropical coun- 
tries, should include susceptible adolescents and adults 
who are at high risk of developing severe varicella and 
resultant complications. Vaccination of susceptible 
women of childbearing age, because of the risks of peri- 
natal and congenital varicella, and health care workers, 
because of the chances of nosocomial exposure to the 
disease, is particularly important and already has been 
advocated.28x29 In tropical countries where a high pro- 
portion of this age group are susceptible, as this and other 
surveys have shown, this advice is especially pertinent. 
Experience in clinical trials has shown that a two- 
dose varicella vaccination schedule is required to pro- 
vide good and long-lasting protection in adults and 
adolescents,30s31 and this has been endorsed by the recent 
recommendations for vaccine use in the United States.32 
Because of the epidemiology of the disease in the 
tropics, it has been suggested that universal varicella 
immunization of all populations living in these areas 
could be justified.33 However, because of the relatively 
high price of the vaccine, and since only 30% of adults 
are susceptible, this would probably not be cost-benefi- 
cial.Although the recall of past chickenpox may be con- 
sidered reliable enough to exclude those not requiring 
vaccination, serologic testing, which is less expensive 
than vaccination, may seem to be a logical policy espe- 
cially for those without a history of varicella. However, 
because serologic testing would require another visit to 
the physician, this would not only increase costs but also 
reduce vaccination compliance.When a decision analysis 
model was used to analyze the cost-effectiveness of pre- 
sumptive vaccination versus serologic testing in children 
and adolescents with negative or uncertain histories of 
varicella, the results showed that presumptive vaccina- 
tion was relatively cost-effective for school aged children 
but not for adolescents3*A cost:benefit analysis to address 
the practicality of serologic testing and presumptive vac- 
cination could help resolve these issues. 
Varicella vaccination programs could also be directed 
at children, in whom one dose of the vaccine is effica- 
cious.30 Varicella vaccine could be conveniently adminis- 
tered to children at the time of school entry, during their 
time at school or even earlier in life when the vaccine 
could be given concomitantly with other routine vacci- 
nations, such as measles-mumps-rubella vaccine, ideally as 
a single-dose tetravalent measles-mumps-rubella-varicella 
vaccine. 
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